PCSK9 and acute coronary syndrome: The use of PCSK9 inhibitors has been assessed in the ODYSSEY Outcomes study, in which alirocumab was compared with placebo in 18,924 patients who had experienced recent acute coronary syndromes and were already receiving optimized statin therapy.